Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)

被引：0
|
作者：
Moore, M. [1 ]
Hall, R. [2 ]
Mcloughlin, E. [2 ]
Melson, J. [1 ]
Horton, B. [3 ]
Mills, A. [4 ]
Gentzler, R. [2 ]
机构：
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
[2] Univ Virginia, Div Hematol Oncol, Charlottesville, VA USA
[3] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, AL USA
[4] Univ Virginia, Pathol, Charlottesville, VA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
IDO1; NSCLC; PD-L1;
D O I：
10.1016/j.jtho.2019.08.1580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-75
引用
收藏
页码：S738 / S738
页数：1
相关论文
共 50 条
  • [1] REAL WORLD DATA ANALYSIS OF OBESITY AND OVERALL SURVIVAL IN NSCLC PATIENTS RECEIVING ANTI-PD-1/PD-L1 IMMUNE CHECKPOINT INHIBITORS.
    Valdes, I.
    Girish, S.
    Mandikian, D.
    Machado, R.
    Wu, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S49 - S49
  • [2] Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas
    Zhang, M. Lisa
    Kem, Marina
    Mooradian, Meghan J.
    Eliane, Jean-Pierre
    Huynh, Tiffany G.
    Iafrate, A. John
    Gainor, Justin F.
    Mino-Kenudson, Mari
    MODERN PATHOLOGY, 2019, 32 (04) : 511 - 523
  • [3] PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients
    Toda, Yu
    Kohashi, Kenichi
    Yamada, Yuichi
    Ishihara, Shin
    Ito, Yoshihiro
    Yamamoto, Hidetaka
    Oda, Yoshinao
    CANCER SCIENCE, 2021, 112 : 514 - 514
  • [4] Expression of Immuoregulators IDO1, and PD-L1 in Gastrointestinal Stromal Tumors
    Matoso, Andres
    Siddique, Ayesha
    Lombardo, Kara A.
    Resnick, Murray B.
    Taliano, Ross
    Wang, Li J.
    MODERN PATHOLOGY, 2017, 30 : 187A - 187A
  • [5] Expression of Immuoregulators IDO1, and PD-L1 in Gastrointestinal Stromal Tumors
    Matoso, Andres
    Siddique, Ayesha
    Lombardo, Kara A.
    Resnick, Murray B.
    Tahano, Ross
    Wang, Li J.
    LABORATORY INVESTIGATION, 2017, 97 : 187A - 187A
  • [6] IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells
    Afshan Fathima Nawas
    Ashley Solmonson
    Boning Gao
    Ralph J. DeBerardinis
    John D. Minna
    Maralice Conacci-Sorrell
    Carole R. Mendelson
    Cell Communication and Signaling, 21
  • [7] IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells
    Nawas, Afshan Fathima
    Solmonson, Ashley
    Gao, Boning
    Deberardinis, Ralph J.
    Minna, John D.
    Conacci-Sorrell, Maralice
    Mendelson, Carole R.
    CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
  • [8] Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK/T-cell lymphoma
    Li, Yajun
    Chen, Kailin
    Chen, Bihua
    Zeng, Ruolan
    He, Yizi
    Wang, Caiqin
    Zhong, Meizuo
    Liu, Xianling
    Chen, Xiaoyan
    Xiao, Ling
    Zhou, Hui
    LEUKEMIA, 2024, 38 (07) : 1553 - 1563
  • [9] Patients' sex and PD-L1 expression jointly associated with overall survival benefits of immune checkpoint inhibitors in cancer
    Yu, Y.
    Li, A.
    Chen, Y.
    Zhang, W.
    Zhong, H.
    Gu, Y.
    Ou, Q.
    Xia, J.
    Lin, D.
    Fu, T.
    Li, L.
    Liu, R.
    Yao, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S713 - S713
  • [10] Indoleamine 2,3-dioxygenase (IDO1), PD-L1, and overall survival (OS) of patients diagnosed with esophageal cancer.
    Rosenberg, Ari
    Wainwright, Derek
    Rademaker, Alfred
    Galvez, Carlos
    Genet, Matthew
    Zhai, Lijie
    Lauing, Kristen
    Villaflor, Victoria Meucci
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345